Top of this page
Skip navigation, go straight to the content
At UCB,
we aspire to be the patient-preferred biotech leader.
To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.
Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.
In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success.
IR events
| Date | Event details |
|---|---|
| 08 September 2021 | Citi’s 16th Annual BioPharma Virtual Conference1/1 virtual meetings & fireside chat |
| 09 September 2021 | KBC Life Sciences & Biotech Conference1/1 virtual meetings |
| 17 September 2021 | BofA Global Healthcare Conference1/1 virtual meetings & fireside chat |
2021 HY results
2020 integrated report
Outlook 2021
Based on UCB’s current assessment of the COVID-19 pandemic, UCB remains confident in the fundamental underlying demand for its products and its prospects for long-term growth. UCB will continue to closely follow evolving COVID-19 pandemic diligently to assess potential near- and mid-term challenges.
The figures of the outlook 2021 as mentioned below were calculated on the same basis as the actual figures for 2020.
2021 revenue
€ 5.45 – 5.65 billion
thanks to current core product growth and new patient populations being served
Adjusted EBITDA
27% - 28%
reflecting the high R&D and marketing & sales investment levels
Core earnings per share
€ 5.60 - € 6.10
based on an average of 189 million shares outstanding
Contact UCB IR team
investor-relations@ucb.com or a specific team member:
- Antje Witte, Head of Investor Relations
Tel: +32 2 559 9414
E-mail: Antje.Witte@ucb.com - Alexander Klein, Investor Relations Lead
Tel: +32 2 559 9948
E-mail: Alex.Klein@ucb.com - Julien Bayet, Investor Relations Manager
Tel: +32 2 559 9580
E-mail: Julien.Bayet@ucb.com
UCB IR App
